13,712 Shares in ResMed Inc. (NYSE:RMD) Bought by Executive Wealth Management LLC

Executive Wealth Management LLC purchased a new stake in ResMed Inc. (NYSE:RMD - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 13,712 shares of the medical equipment provider's stock, valued at approximately $3,347,000.

Several other institutional investors have also made changes to their positions in the stock. True Wealth Design LLC lifted its stake in ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 110 shares during the last quarter. OFI Invest Asset Management bought a new stake in ResMed during the second quarter worth $32,000. Ashton Thomas Securities LLC bought a new stake in ResMed during the third quarter worth $34,000. Financial Connections Group Inc. bought a new stake in ResMed during the second quarter worth $37,000. Finally, Blue Trust Inc. increased its holdings in shares of ResMed by 182.7% during the second quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider's stock worth $42,000 after buying an additional 137 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Bank of America upped their price target on shares of ResMed from $240.00 to $270.00 and gave the stock a "buy" rating in a report on Thursday, September 26th. Royal Bank of Canada upped their price target on shares of ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a report on Friday, October 25th. Baird R W upgraded shares of ResMed to a "strong-buy" rating in a report on Tuesday, September 24th. KeyCorp upped their price target on shares of ResMed from $251.00 to $266.00 and gave the stock an "overweight" rating in a report on Friday, October 25th. Finally, StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $225.70.

Insider Buying and Selling at ResMed

In other news, CEO Michael J. Farrell sold 14,683 shares of ResMed stock in a transaction on Monday, October 7th. The shares were sold at an average price of $231.91, for a total transaction of $3,405,134.53. Following the completion of the sale, the chief executive officer now directly owns 464,169 shares of the company's stock, valued at approximately $107,645,432.79. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kaushik Ghoshal sold 5,000 shares of ResMed stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the sale, the insider now directly owns 21,788 shares of the company's stock, valued at $5,502,777.28. This represents a 18.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 52,725 shares of company stock valued at $12,516,248 in the last three months. Company insiders own 0.71% of the company's stock.

ResMed Stock Performance

ResMed stock traded up $0.46 during mid-day trading on Tuesday, reaching $245.22. The company's stock had a trading volume of 503,618 shares, compared to its average volume of 1,023,487. ResMed Inc. has a 12-month low of $162.18 and a 12-month high of $260.49. The company has a market capitalization of $36.00 billion, a P/E ratio of 32.48, a PEG ratio of 1.75 and a beta of 0.68. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92. The firm's fifty day moving average price is $242.31 and its two-hundred day moving average price is $226.81.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating analysts' consensus estimates of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The business had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same period in the previous year, the business earned $1.64 EPS. ResMed's revenue was up 11.1% compared to the same quarter last year. Sell-side analysts predict that ResMed Inc. will post 9.34 EPS for the current fiscal year.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 0.86%. The ex-dividend date is Thursday, November 7th. ResMed's payout ratio is 28.08%.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.